News
• Agreement grants access to patient genotypes and clinical data curated by Professor Ammar Al-Chalabi’s Group based at King’s College London
• Motor Neurone Disease (MND) Association supports new analysis of patient data to bring cutting edge analysis tools to improve understanding of disease
• Enables PrecisionLife to establish precision neuroscience R&D partnerships to advance new patient stratification biomarkers, diagnostics and treatment approaches
Cambridge and Saffron Walden, UK, 21st April 2023 / Sciad Newswire / Domainex is honoured to announce it has received a King’s Award for Enterprise: International Trade 2023. This prestigious award recognises the company’s outstanding growth in international trade over three years (2019-2021) which amounted to a more than one hundred per cent increase in international revenues during the period.
NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
- Funding targets a critical unmet clinical need to treat autoimmunity, which affects around 300 million people globally
- Awarded as part of £25 million Innovate UK Biomedical Catalyst fund
- Sharpest rise in CFO optimism since 2020;
- Survey shows biggest decline on record for CFOs’ perceptions of external uncertainty;
- Brexit and energy risks ease;
- CFOs see artificial intelligence driving investment and productivity, but are divided on impact on jobs within the workforce.
Sentiment among finance leaders of the UK’s largest firms has improved significantly since the start of the year, according to Deloitte’s UK CFO Survey Q1 2023.
20th March 2023 Nijmegen, The Netherlands and Biocity Nottingham UK
Alveron Pharma announces that it has commenced a Phase 1 clinical study for OKL-1111, a new drug for the treatment of Intracranial Haemorrhage (ICH) and other life-threatening bleeds associated with the use of anticoagulants or platelet inhibitors. The clinical trial is taking place in the UK and will investigate safety, pharmacokinetics and pharmacodynamics in man.
Do you have a winning commercialisation strategy?
If you are a startup that:
- Is developing therapeutic innovations
- Has obtained a first proof-of-concept OR a £1-3m funding
- Has integrated digital technologies (ML/AI) in the R&D workflow OR is planning to
Apply to SBC Catalyser programme!
CHARM Therapeutics is a 3D deep learning research company discovering and developing transformational medicines.
The facility will act as the new research & development (R&D) site for CHARM Therapeutics, providing the Company with the necessary capacity to support its growth plans as it continues to develop its transformational oncology pipeline.
The Skeletal Muscle Differentiation kit from AMSBIO provides a unique protocol to differentiate human pluripotent stem cells to skeletal muscle with high yields and without cell sorting or genetic manipulation.